Athena Athena

X
[{"orgOrder":0,"company":"Celeris Therapeutics","sponsor":"Pace Ventures Enigma","pharmaFlowCategory":"D","amount":"$4.4 million","upfrontCash":"Undisclosed","newsHeadline":"CelerisTx Announces $4.4m Financing to Advance Pipeline of Novel Proximity Inducing Compound","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"February 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery"}]

Find Clinical Drug Pipeline Developments & Deals by Celeris Therapeutics

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            The funding will be used to build our laboratory site in Graz, Austria, and further fuel three in-house drug programs around neurology and oncology. This means a substantial acceleration on a global scale of the platform.

            Lead Product(s): Undisclosed

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: Pace Ventures Enigma

            Deal Size: $4.4 million Upfront Cash: Undisclosed

            Deal Type: Financing February 10, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY